G. Zibetti Dal Molin

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma

R. Coleman, F. Maluf, G. Zibetti Dal Molin, 2018, Gynecologic Oncology Research and Practice.

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors

R. Coleman, S. Westin, P. Msaouel, 2019, International Journal of Gynecological Cancer.

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers

R. Coleman, A. Chelariu-Raicu, G. Zibetti Dal Molin, 2020, International Journal of Gynecological Cancer.

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

G. Iyer, J. Tabernero, G. Folprecht, 2023, Journal of Clinical Oncology.